Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
IMC-2032 by ImmuneCyte for Premature Ageing: Likelihood of Approval
IMC-2032 is under clinical development by ImmuneCyte and currently in Phase I for Premature Ageing. According to GlobalData, Phase I...